Risk Factors for HSV Encephalitis
HSV encephalitis can affect all age groups and occurs year-round, but specific patient populations face substantially elevated risk, particularly immunocompromised individuals, those receiving cranial radiation therapy with corticosteroids, older adults (especially >63 years), and carriers of specific genetic variants.
Patient Demographics and General Risk Factors
- Age extremes carry differential risk: HSV-1 infection predominates in adults while HSV-2 is more common in neonates 1
- All age groups are susceptible across all seasons, making HSV-1 one of the most common causes of identified sporadic encephalitis worldwide 1
- Older age is a critical mortality risk factor: patients >63 years have significantly higher cumulative mortality (HR 1.096,95% CI 1.04-1.15, p<0.001) 2
Immunocompromised States
Cancer patients, particularly those receiving specific therapies, face markedly increased risk:
- Cranial radiation therapy appears to substantially increase HSE incidence—in one cancer center cohort, 4 of 7 HSE patients had received cranial RT from a pool of 997 RT-treated patients, suggesting incidence far exceeding the general population rate of 2-4 cases per million annually 3
- Chemotherapy was recently administered in 5 of 7 cancer patients who developed HSE 3
- Corticosteroid therapy, particularly dexamethasone, was present in 3 of 7 cancer patients with HSE 3
- The combination of brain irradiation plus corticosteroids may synergistically trigger HSV reactivation from latent virus in sensory ganglia or brain parenchyma 4
Genetic Susceptibility
Specific apolipoprotein E (apoE) genotypes modify HSE risk:
- ApoE ε2 allele carriers have significantly elevated HSE risk (OR 4.6,95% CI 2.0-10.8) with an allele frequency of 26% in HSE patients versus 7% in controls 5
- IRF3 gene variants show autosomal dominant association with symptomatic HSE compared to asymptomatic seropositive controls 6
- MX1 gene variants demonstrate autosomal recessive association with symptomatic disease 6
Clinical Presentation Risk Indicators
Certain clinical features at presentation correlate with HSE diagnosis:
- Absence of prior neurological history (OR 6.25,95% CI 2.22-16.7) 7
- Seizure occurrence (OR 8.09,95% CI 2.73-23.94) 7
- Systolic blood pressure ≥140 mmHg (OR 5.11,95% CI 1.77-14.77) 7
- C-reactive protein <10 mg/L (OR 9.27,95% CI 2.98-28.88), suggesting lower systemic inflammatory response 7
Mortality Risk Factors
Once HSE develops, specific factors predict worse outcomes:
- Cancer comorbidity dramatically increases mortality risk (HR 11.02,95% CI 2.76-43.9, p<0.001) 2
- Lower lymphocyte count in CSF predicts higher mortality (HR 0.97,95% CI 0.95-0.99, p=0.032) 2
- Delayed treatment initiation: patients who died had longer time to acyclovir (4.01±5.69 vs 1.96±3.58 days, p=0.026) 2
- Long-term mortality is substantial: 55% of HSV-1 encephalitis patients died during mean 6.25-year follow-up, with 10 deaths occurring within the first year 2
Important Clinical Caveats
Immunocompromised patients may present atypically:
- Normal CSF white blood cell counts occurred in 4 of 7 cancer patients with HSE, particularly those with prior radiation and dexamethasone exposure 3
- False-negative CSF PCR can occur—one confirmed autopsy case had negative CSF HSV PCR 3
- These atypical presentations mandate high clinical suspicion and consideration of empiric acyclovir even with reassuring CSF findings in high-risk populations 3